Project Grant R35GM159930
- The University of Pennsylvania was awarded a $443,806 Project Grant by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The grant supports fundamental scientific research investigating the collective impacts and regulatory mechanisms of multiple enzyme-mediated modifications across distinct RNA species, particularly in the areas of mRNA, tRNA, and rRNA. The research aims to uncover the extent of crosstalk in...
- This $1,169,317 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a molecular toolbox for non-invasive methods to kill cells in situ via specific cell death pathways using safe, tunable temperature stimuli. The objective is to generate single protein constructs that can trigger apoptosis, necroptosis, or pyroptosis...
- This $406,250 Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports two primary research directions at the University of Pennsylvania. The first research direction focuses on understanding how transcription factor families coordinate complex developmental pathways to generate diverse cellular morphologies and cell types, with a focus on identifying new mechanisms of transcription...
- This Project Grant award, valued at $453,750.00 and awarded on August 8, 2025, supports research by The General Hospital Corporation (doing business as Massachusetts General Hospital) under the National Institute of General Medical Sciences' (NIGMS) Biomedical Research and Research Training program (CFDA 93.859). The research aims to explore how metabolic pathways control the transition between cell viability, pyroptosis (a lytic cell death program), and apoptosis (non-lytic cell death)....
- The National Institute of General Medical Sciences (NIGMS), under the federal Biomedical Research and Research Training program (CFDA 93.859), awarded a $412,500 Project Grant to the University of South Florida. The grant supports a research program focused on understanding the molecular mechanisms of cell death and developing small molecule inhibitors to treat diseases associated with dysregulated cell death, including systemic inflammatory response syndrome (SIRS), infection, and heart...
- This Project Grant award for $316,368.00 was provided by the National Institute of General Medical Sciences (NIGMS), which administers the Biomedical Research and Research Training (CFDA 93.859) federal grant program. The grant will fund research to understand the mechanisms of metabolic adaptation in cells, focusing on the autophagy and cytochrome P450 pathways. The research aims to elucidate how these pathways respond to nutrient scarcity and chemical stressors, using advanced genomics,...
- The federal Project Grant award of $420,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to identify the molecular mechanisms of mitochondrial dysfunction in pathological stress conditions. The primary objective is to investigate the processes of oxidative phosphorylation and mitochondrial membrane potential disruption, which can lead to cell death and tissue damage in various diseases....
- This $147,486 Project Grant award from the National Institute of General Medical Sciences (CFDA 93.859 Biomedical Research and Research Training program) supports research at the University of Pennsylvania to investigate the role of post-translational modifications, such as protein phosphorylation and glycation, in how the bacterium E. coli responds to and protects itself from the toxic compound methylglyoxal. Specifically, the research aims to delineate the mechanisms by which modifications...
- This $406,250 Project Grant was awarded on August 1, 2025 by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859). The project aims to develop novel computational methods that can accurately characterize the reorganization of water structure and its impact on the thermodynamics and kinetics of protein interactions. This will be applied to three specific projects: (1) interactions between reader proteins and...
- This federal Project Grant award, valued at $365,625.00 and issued by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), aims to elucidate the mechanisms by which TET family enzymes act on 5-methylcytosine in genomic DNA and to exploit these insights to devise controllable epigenome editors. The research, conducted by The Trustees of the University of Pennsylvania, will focus on understanding cytosine...
This federal Project Grant award of $446,875.00, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), supports research to decipher novel cell death mechanisms and metabolic reprogramming in response to microenvironmental stress. The primary awardee, The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, will leverage their expertise in cell engineering and metabolic profiling to (i) characterize the precise mechanism of cell death in non-targeted cells exposed to immune activation, and (ii) investigate how surviving cells undergo metabolic reprogramming to adapt to these challenging microenvironmental conditions. This research aims to advance the fundamental understanding of biological processes and has the potential to yield insights with far-reaching implications for various fields. The award period runs from August 8, 2025 through June 30, 2030.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $446.9k | 8/7/25 |